• Top
• Meeting abstract

This article is part of the supplement: 13th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint Meeting with the Austrian Society of Toxicology (ASTOX) and the Hungarian Society for Experimental and Clinical Pharmacology (MFT) .

Meeting abstract

Daptomycin elimination by continuous venovenous hemofiltration: in vitro evaluation of factors influencing sieving and membrane adsorption

Claudia Wagner¹, Ilka Steiner² and Markus Zeitlinger¹

¹Department of Clinical Pharmacology, Medical University of Vienna, Austria

²Institute of Pharmacology, Center for Biomolecular Medicine and Pharmacology, Medical University of Vienna, Austria

author email corresponding author email

from 13th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint Meeting with the Austrian Society of Toxicology (ASTOX) and the Hungarian Society for Experimental and Clinical Pharmacology (MFT)
Vienna, Austria. 22–24 November 2007

BMC Pharmacology 2007, 7(Suppl 2):A21doi:10.1186/1471-2210-7-S2-A21

The electronic version of this abstract is the complete one and can be found online at: http://www.biomedcentral.com/1471-2210/7/S2/A21

Published:

14 November 2007

© 2007 Wagner et al; licensee BioMed Central Ltd.

Meeting abstract

The present in vitro study set out to determine for the first time the continuous venovenous hemofiltration (CVVH) clearance of the novel lipopetide antibiotic, daptomycin, from human whole blood. Factors influencing daptomycin sieving and membrane adsorption were investigated in an in vitro setting. A recirculation model was established and daptomycin was added to the simulated blood circuit at different concentrations and in different solvent systems. The concentration of daptomycin over time in the modelled blood compartment and in ultrafiltrate was measured by HPLC. Mean sieving coefficients (SCs) of daptomycin over time were 1 ± 0.05, 0.3 ± 0.02 and 0.4 ± 0.03 in Ringer lactate, Ringer lactate containing human albumin and plasma, respectively. The CVVH clearance of daptomycin from whole blood exceeded the physiological clearance in an individual with normal renal function. Adsorption of daptomycin to synthetic surfaces proved moderate, resulting in loss of around 20% of the initial dose at 1 hour after the start of CVVH. Since mean SCs of daptomycin in protein-containing media were higher than the free fraction in plasma, our results suggest that besides protein binding, unknown factors such as intracellular drug partitioning influence sieving of daptomycin during hemofiltration. Due to the high in vitro CVVH clearance of daptomycin we determined from human whole blood, we recommend monitoring of daptomycin concentrations in patients undergoing hemofiltration.

Have something to say? Post a comment on this article!